Seattle Genetics strikes potential $4.2B deal for breast cancer drug
September 14, 2020 at 18:14 PM EDT
New Jersey-based Merck & Co. Inc. will help Seattle Genetics globally develop a drug that targets breast cancer and other solid tumors.
